Targeting MCL-1 protein to treat cancer: opportunities and challenges
Frontiers in Oncology · 31.07.2023 · 13
DOI: 10.3389/fonc.2023.1226289 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 31.07.2023. Verfasst von Shady I Tantawy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CLL Global Research Foundation, University of Texas MD Anderson Cancer Center.
Abstract (Originalsprache)
Evading apoptosis has been linked to tumor development and chemoresistance. One mechanism for this evasion is the overexpression of prosurvival B-cell lymphoma-2 (BCL-2) family proteins, which gives cancer cells a survival advantage. Mcl-1 , a member of the BCL-2 family, is among the most frequently amplified genes in cancer. Targeting myeloid cell leukemia-1 (MCL-1) protein is a successful strategy to induce apoptosis and overcome tumor resistance to chemotherapy and targeted therapy. Various strategies to inhibit the antiapoptotic activity of MCL-1 protein, including transcription, translation, and the degradation of MCL-1 protein, have been tested. Neutralizing MCL-1’s function by targeting its interactions with other proteins via BCL-2 interacting mediator (BIM) S 2A has been shown to be an equally effective approach. Encouraged by the design of venetoclax and its efficacy in chronic lymphocytic leukemia, scientists have developed other BCL-2 homology (BH3) mimetics—particularly MCL-1 inhibitors (MCL-1i)—that are currently in clinical trials for various cancers. While extensive reviews of MCL-1i are available, critical analyses focusing on the challenges of MCL-1i and their optimization are lacking. In this review, we discuss the current knowledge regarding clinically relevant MCL-1i and focus on predictive biomarkers of response, mechanisms of resistance, major issues associated with use of MCL-1i, and the future use of and maximization of the benefits from these agents.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Förderung
- CLL Global Research Foundation
- University of Texas MD Anderson Cancer Center
Zitieren
APA
Tantawy, S. I., Timofeeva, N., Sarkar, A., & Gandhi, V. (2023). Targeting MCL-1 protein to treat cancer: opportunities and challenges. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1226289
Vancouver
Tantawy SI, Timofeeva N, Sarkar A, Gandhi V. Targeting MCL-1 protein to treat cancer: opportunities and challenges. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1226289
BibTeX
@article{Tantawy2023,
author = {Tantawy, Shady I and Timofeeva, Natalia and Sarkar, Aloke and Gandhi, Varsha},
title = {Targeting MCL-1 protein to treat cancer: opportunities and challenges},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1226289}
}
EUVIMED